Primary Outcome Measures:
- Evaluation of presence / absence of CTC on the global survival [ Time Frame: from Baseline in Systolic Blood Pressure at 6 months ] [ Designated as safety issue: No ]
- Value forecasts of the presence / absence of CTC on the global survival estimated by the estimation and the test of meaning at 0 of the immediate relative risk (fate ratio) in a model at proportional risk.
Secondary Outcome Measures:
- Value forecasts of the number of CTC on the global survival estimated by the risk [ Time Frame: from Baseline in Systolic Blood Pressure at 6 months ] [ Designated as safety issue: No ]
- Value forecasts of the number of CTC on the global survival estimated by the immediate relative risk Value forecasts of the presence / absence and the number of CTC on the survival without second offense(recurrence) or metastasis estimated by the immediate relative risk
Eligibility Criteria
- Inclusion Criteria:
- For the patients:
-
- Age > 18 years
- Patient having been operated for a strong suspicion of pleural malignant tumoral lesion corresponding to a primitive pleural mesothelioma
- Signed patient consent
- For the control subjects:
- Age > 18 years
- Unhurt of any malignant or mild tumoral pathology or patients that must benefit from a surgical procedure for a benign lesion in other organ than the pleura or a pulmonary non tumoral lesion
- Signed patient consent
- Exclusion Criteria:
-
- Patient with histories of cancer or the other synchronous cancer
- Patient with additives treatments
- Patient according to treatments additives other than protocols codified (in particular, platinum navelbine or gemcitabine platinum) for stages II
- HIV, hepatitis B or C infections
- Pregnant women
